The vulnerable atherosclerotic plaque: Pathogenesis and therapeutic approach

Cardiovascular Pathology

Volumn 13, Issue 3, 2004, Pages 125-138

  Aikawa, Masanori ^a,b   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; MACROPHAGE ACTIVATING FACTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY INFILTRATE; MACROPHAGE; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOGENICITY;

EID: 1842662594     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(04)00004-3     Document Type: Article

References (134)

1. Aikawa M., Libby P. Vascular inflammation and activation: new targets for lipid lowering. Eur Heart J Suppl. 3:2001;B3-B11.
2. Libby P., Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 8:2002;1257-1262.
3. Stary H.C. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis. 9:1989;I19-I32.
4. Aikawa M., Sivam P.N., Kuro-o M., Kimura K., Nakahara K., Takewaki S., Ueda M., Yamaguchi H., Yazaki Y., Periasamy M., Nagai R. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 73:1993;1000-1012.
5. Munro J.M., Cotran R.S. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 58:1988;249-261.
6. Libby P. Inflammation in atherosclerosis. Nature. 420:2002;868-874.
7. Libby P., Aikawa M. Evolution and stabilization of vulnerable atherosclerotic plaques. Jpn Circ J. 65:2001;473-479.
8. Stamler J., Shekelle R. Dietary cholesterol and human coronary heart disease. The epidemiologic evidence. Arch Pathol Lab Med. 112:1988;1032-1040.
9. Libby P., Aikawa M., Schonbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta. 1529:2000;299-309.
10. LaRosa J.C., Hunninghake D., Bush D., Criqui M.H., Getz G.S., Gotto A.M., Grundy S.M., Rakita L., Robertson R.M., Weisfeldt MLet al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues American Heart Association. Circulation. 81:1990;1721-1733.
11. Anitschkow N., Chalatow S. On experimental cholesterin steatosis and its significance in the origin of some pathological processes (1913). Arteriosclerosis. 3:1983;178-182. Reprint.
12. Vesselinovitch D. Animal models and the study of atherosclerosis. Arch Pathol Lab Med. 112:1988;1011-1017.
13. Armstrong M.L., Heistad D.D. Animal models of atherosclerosis. Atherosclerosis. 85:1990;15-23.
14. Aikawa M., Fukumoto Y., Rabkin E., Libby P. Rabbit models of atherosclerosis. Simon D.I., Rogers C. Vascular disease and injury: preclinical research. 2000;175-191 Humana Press, Totowa (NJ).
15. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 320:1989;915-924.
16. Miller Y.I., Chang M.K., Binder C.J., Shaw P.X., Witztum J.L. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 14:2003;437-445.
17. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:1995;2488-2496.
18. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Circulation 2003;108:1912-6, 2034-2040.
19. Haberland M.E., Fong D., Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215-218.
20. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
21. Aikawa M., Sugiyama S., Hill C., Voglic S., Rabkin E., Fukumoto Y., Schoen F., Witztum J.L., Libby P. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation. 106:2002;1390-1396.
22. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA. 84:1987;2995-2998.
23. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., Gerrity R., Schwartz C.J., Fogelman A.M. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 87:1990;5134-5138.
24. Rosenfeld M.E., Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis. 10:1990;680-687.
25. Gordon D., Reidy M.A., Benditt E.P., Schwartz S.M. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA. 87:1990;4600-4604.
26. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., Shiomi M., Schoen F.J., Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:2001;276-283.
27. Sakai M., Kobori S., Miyazaki A., Horiuchi S. Macrophage proliferation in atherosclerosis. Curr Opin Lipidol. 11:2000;503-509.
28. Collins T., Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 107:2001;255-264.
29. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 343:1990;531-535.
30. Griendling K.K., Alexander R.W. Oxidative stress and cardiovascular disease. Circulation. 96:1997;3264-3265.
31. Davies M.J., Thomas A.C. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 53:1985;363-373.
32. Hackett D., Davies G., Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J. 9:1988;1317-1323.
33. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., Hjemdahl-Monsen C.E., Leavy J., Weiss M., Borrico S., Gorlin R., Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 12:1988;56-62.
34. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 69:1993;377-381.
35. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
36. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., Fallon J.T. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 90:1994;775-778.
37. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 92:2003;827-839.
38. Chase A.J., Newby A.C. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res. 40:2003;329-343.
39. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., Schoen F.J., Kelly R.A., Werb Z., Libby P., Lee R.T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 106:2000;55-62.
40. Rabkin E., Aikawa M., Stone J.R., Fukumoto Y., Libby P., Schoen F.J. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 104:2001;2525-2532.
41. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 3:2002;207-214.
42. Jones C.B., Sane D.C., Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 59:2003;812-823.
43. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503.
44. Sukhova G., Schoenbeck U., Rabkin E., Schoen F., Poole A., Billinghurst R., Libby P. Evidence of increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 99:1999;2503-2509.
45. Herman M.P., Sukhova G.K., Libby P., Gerdes N., Tang N., Horton D.B., Kilbride M., Breitbart R.E., Chun M., Schonbeck U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 104:2001;1899-1904.
46. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 336:1997;1276-1282.
47. Lee E., Grodzinsky A.J., Libby P., Clinton S.K., Lark M.W., Lee R.T. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol. 15:1995;2284-2289.
48. Lee R.T., Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 17:1997;1859-1867.
49. Loree H.M., Kamm R.D., Stringfellow R.G., Lee R.T. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 71:1992;850-858.
50. Loree H.M., Tobias B.J., Gibson L.J., Kamm R.D., Small D.M., Lee R.T. Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb. 14:1994;230-234.
51. Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 86:1989;2839-2843.
52. Lupu F., Bergonzelli G.E., Heim D.A., Cousin E., Genton C.Y., Bachmann F., Kruithof E.K. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 13:1993;1090-1100.
53. Heinecke J.W. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radic Biol Med. 32:2002;1090-1101.
54. Sugiyama S., Okada Y., Sukhova G.K., Virmani R., Heinecke J.W., Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 158:2001;879-891.
55. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 98:1996;2572-2579.
56. Rajavashisth T.B., Liao J.K., Galis Z.S., Tripathi S., Laufs U., Tripathi J., Chai N.N., Xu X.P., Jovinge S., Shah P.K., Libby P. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 274:1999;11924-11929.
57. Kume N., Cybulsky M.I., Gimbrone M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 90:1992;1138-1144.
58. Khan B.V., Parthasarathy S.S., Alexander R.W., Medford R.M. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest. 95:1995;1262-1270.
59. Li H., Cybulsky M.I., Gimbrone M.A., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 13:1993;197-204.
60. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., Davis V., Gutierrez-Ramos J.C., Connelly P.W., Milstone D.S. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 107:2001;1255-1262.
61. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 2:1998;275-281.
62. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:1998;894-897.
63. Tsao P.S., McEvoy L.M., Drexler H., Butcher E.C., Cooke J.P. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 89:1994;2176-2182.
64. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A., Shin W.S., Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 96:1995;60-68.
65. Khan B.V., Harrison D.G., Olbrych M.T., Alexander R.W., Medford R.M. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA. 93:1996;9114-9119.
66. Tsao P.S., Wang B., Buitrago R., Shyy J.Y., Cooke J.P. Nitric oxide regulates monocyte chemotactic protein-1. Circulation. 96:1997;934-940.
67. Oemar B.S., Tschudi M.R., Godoy N., Brovkovich V., Malinski T., Luscher T.F. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 97:1998;2494-2498.
68. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 270:1995;319-324.
69. Farb A., Burke A.P., Tang A.L., Liang T.Y., Mannan P., Smialek J., Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1996;1354-1363.
70. Schneiderman J., Sawdey M.S., Keeton M.R., Bordin G.M., Bernstein E.F., Dilley R.B., Loskutoff D.J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 89:1992;6998-7002.
71. Gotto A.M., Farmer J.A. Lipid-lowering trials. Braunwald E., Zipes D.P., Libby P. Heart disease: a text book of cardiovascular medicine. 2001;126-146 WB Saunders, Philadelphia.
72. Libby P., Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 91:2003;4B-8B.
73. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
74. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
75. Small D.M. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis. 8:1988;103-129.
76. Wissler R.W., Vesselinovitch D. Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animal models. Am J Cardiol. 65:1990;33F-40F.
77. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 110:2002;285-288.
78. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 97:1998;2433-2444.
79. Aikawa M., Voglic S.J., Sugiyama S., Rabkin E., Taubman M.B., Fallon J.T., Libby P. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation. 100:1999;1215-1222.
80. Aikawa M., Rabkin E., Voglic S.J., Shing H., Nagai R., Schoen F.J., Libby P. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res. 83:1998;1015-1026.
81. Kockx M.M., De Meyer G.R., Buyssens N., Knaapen M.W., Bult H., Herman A.G. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res. 83:1998;378-387.
82. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933.
83. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., Shiomi M., Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 103:2001;993-999.
84. Ohara Y., Peterson T.E., Sayegh H.S., Subramanian R.R., Wilcox J.N., Harrison D.G. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 92:1995;898-903.
85. Palinski W., Tangirala R.K., Miller E., Young S.G., Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 15:1995;1569-1576.
86. Cyrus T., Witztum J.L., Rader D.J., Tangirala R., Fazio S., Linton M.F., Funk C.D. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 103:1999;1597-1604.
87. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
88. Rollins B.J. Chemokines. Blood. 90:1997;909-928.
89. O'Brien K.D., Allen M.D., McDonald T.O., Chait A., Harlan J.M., Fishbein D., McCarty J., Ferguson M., Hudkins K., Benjamin C.D., Lobb R., Alpers C.E. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest. 92:1993;945-951.
90. Brogi E., Winkles J.A., Underwood R., Clinton S.K., Alberts G.F., Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest. 92:1993;2408-2418.
91. Tenaglia A.N., Peters K.G., Sketch M.H., Annex B.H. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J. 135:1998;10-14.
92. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 7:2001;425-429.
93. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 99:1999;1726-1732.
94. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143.
95. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 41:2003;37S-42S.
96. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
97. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
98. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 18:1998;1671-1678.
99. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Edigo J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 83:1998;490-500.
100. Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 20:2000;556-562.
101. Sakai M., Kobori S., Matsumura T., Biwa T., Sato Y., Takemura T., Hakamata H., Horiuchi S., Shichiri M. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 133:1997;51-59.
102. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta. 1345:1997;259-268.
103. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 273:1998;24266-24271.
104. Hernandez-Perera O., Perez-Sala D., Soria E., Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 87:2000;616-622.
105. Feron O., Dessy C., Desager J.P., Balligand J.L. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 103:2001;113-118.
106. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
107. Yoshida M., Sawada T., Ishii H., Gerszten R.E., Rosenzweig A., Gimbrone M.A., Yasukochi Y., Numano F. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 21:2001;1165-1171.
108. Eto M., Kozai T., Cosentino F., Joch H., Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 105:2002;1756-1759.
109. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 83:1998;683-690.
110. Weis M., Heeschen C., Glassford A.J., Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation. 105:2002;739-745.
111. Urbich C., Dernbach E., Zeiher A.M., Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 90:2002;737-744.
112. Walter D.H., Rittig K., Bahlmann F.H., Kirchmair R., Silver M., Murayama T., Nishimura H., Losordo D.W., Asahara T., Isner J.M. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 105:2002;3017-3024.
113. Egashira K., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Inou T., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
114. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
115. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
116. Wilson S.H., Simari R.D., Best P.J., Peterson T.E., Lerman L.O., Aviram M., Nath K.A., Holmes D.R., Lerman A. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 21:2001;122-128.
117. Tsunekawa T., Hayashi T., Kano H., Sumi D., Matsui-Hirai H., Thakur N.K., Egashira K., Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 104:2001;376-379.
118. Wassmann S., Faul A., Hennen B., Scheller B., Bohm M., Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 93:2003;e98-103.
119. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
120. Shimizu K., Aikawa M., Takayama K., Libby P., Mitchell R.N. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation. 108:2003;2113-2120.
121. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 98:1998;839-844.
122. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
123. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 326:2003;1423.
124. Kinlay S., Timms T., Clark M., Karam C., Bilodeau T., Ridker P.M., Rifai N., Carlson W., Lloyd-Jones D.M., Johnstone M., Rubenstein J., Alexander S., Orav J., Stone P.H. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 89:2002;1205-1207.
125. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 106:2002;2055-2060.
126. van de Ree M.A., Huisman M.V., Princen H.M., Meinders A.E., Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 166:2003;129-135.
127. Kinlay S., Schwartz G.G., Olsson A.G., Rifai N., Leslie S.J., Sasiela W.J., Szarek M., Libby P., Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 108:2003;1560-1566.
128. Weiss D., Sorescu D., Taylor W.R. Angiotensin II and atherosclerosis. Am J Cardiol. 87:2001;25C-32C.
129. Bocan T.M., Krause B.R., Rosebury W.S., Mueller S.B., Lu X., Dagle C., Major T., Lathia C., Lee H. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 20:2000;70-79.
130. Perrey S., Legendre C., Matsuura A., Guffroy C., Binet J., Ohbayashi S., Tanaka T., Ortuno J.C., Matsukura T., Laugel T., Padovani P., Bellamy F., Edgar A.D. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis. 155:2001;359-370.
131. Ziouzenkova O., Perrey S., Marx N., Bacqueville D., Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep. 4:2002;59-64.
132. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., Fay W.P., Simon D.I., Edelman E.R. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 108:2003;512-515.
133. Fayad Z.A., Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 89:2001;305-316.
134. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 9:2003;123-128.